Stellar(US) | $2,700,000 | (Jan 9, 2025)
XyloCor Therapeutics, Inc. | $67,500,000 | (Jan 9, 2025)
Aspect Biosystems
Canada
- Vancouver, BC
- 09/01/2025
- Series B
- $115,000,000
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of bioprinted tissue therapeutics across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity.
- Industry Biotechnology Research
- Website https://www.aspectbiosystems.com/
- LinkedIn https://www.linkedin.com/company/aspect-biosystems/
Related People
Tamer MohamedFounder
Canada -
Vancouver, British Columbia
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials. Aspect is advancing a pipeline of bioprinted tissue therapeutics across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease. Aspect's pipeline development strategy involves both proprietary programs as well as strategic partnerships, including a collaboration with Novo Nordisk focused on diabetes and obesity.
Relief Cardiovascular | $12,000,000 | (Jan 9, 2025)
VitVio | $2,000,000 | (Jan 9, 2025)
Qualified Health | $30,000,000 | (Jan 9, 2025)
Evergreen Nephrology | $130,000,000 | (Jan 9, 2025)
UNLISTED | $2,250,000 | (Jan 9, 2025)
Zeto / Rapid Full-Montage EEG | $31,000,000 | (Jan 9, 2025)
Red Rover Health, Inc. | $4,000,000 | (Jan 9, 2025)
Deep Vector | $1,500,000 | (Jan 9, 2025)
Ubiety Technologies, Inc. | $10,000,000 | (Jan 9, 2025)